<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE Annotation PUBLIC "-//GENIA//DTD GENIA ANNOTATION EVENT 2.0//EN" "../GENIAtypes/GENIA_event_20.dtd">
<Annotation created="17/07/2006" annotates="http://www.ncbi.nlm.nih.gov/entrez/eutils/efetch.fcgi?db=pubmed&amp;retmode=xml&amp;rettype=medline&amp;id=8707445" creator="Junko Matsuura">
<PubmedArticleSet>
<PubmedArticle>
<MedlineCitation>
<PMID>8707445</PMID>
<Article>
<ArticleTitle>
<sentence id="S1"><term sem="Other" id="T1" lex="cytokine-modulating_activity"><term sem="Protein_family_or_group" id="T2" lex="cytokine">Cytokine</term>-modulating activity</term> of <term sem="Organic_compound_other" id="T3" lex="tepoxalin">tepoxalin</term>, a new potential <term sem="Other" id="T4" lex="antirheumatic">antirheumatic</term>.</sentence>
<event id="E1">
<type class="Regulation" />
<theme idref="T2" />
<cause idref="T3" />
<clue>Cytokine-<clueType>modulating activity</clueType> <linkCause>of</linkCause> tepoxalin, a new potential antirheumatic.</clue>
</event>
</ArticleTitle>
<Abstract>
<AbstractText>
<sentence id="S2"><term sem="Organic_compound_other" id="T5" lex="tepoxalin">Tepoxalin</term> is a new dual <term sem="Organic_compound_other" id="T6" lex="cyclooxygenase/5-lipoxygenase_anti-inflammatory_compound">cyclooxygenase/5-lipoxygenase anti-inflammatory compound</term> currently under clinical investigation.</sentence>
<sentence id="S3">It has been shown to possess <term sem="Other" id="T7" lex="anti-inflammatory_activity">anti-<term sem="Other" id="A1">inflammatory activity</term></term> in a variety of <term sem="Multicellular_organism_natural" id="T8" lex="animal_model">animal models</term> and more recently to inhibit <term sem="Other" id="T9" lex="IL-2_induced_signal_transduction"><term sem="Protein_molecule" id="T10" lex="IL-2">IL-2</term> induced <term sem="Other" id="A2">signal transduction</term></term>.</sentence>
<event id="E2">
<type class="Negative_regulation" />
<theme idref="A1" />
<cause idref="T5" />
<clue><corefCause>It</corefCause> has been shown to possess <clueType>anti</clueType>-inflammatory activity <clueLoc>in a variety of animal models</clueLoc> and more recently to inhibit IL-2 induced signal transduction.</clue>
</event>
<event id="E3">
<type class="Positive_regulation" />
<theme idref="A2" />
<cause idref="T10" />
<clue>It has been shown to possess anti-inflammatory activity in a variety of animal models and more recently to inhibit IL-2 <clueType>induced</clueType> signal transduction.</clue>
</event>
<event id="E4">
<type class="Negative_regulation" />
<theme idref="E3" />
<cause idref="T5" />
<clue>It has been shown to possess anti-inflammatory activity in a variety of animal models and more recently to <clueType>inhibit</clueType> IL-2 induced signal transduction.</clue>
</event>
<sentence id="S4">The current study was conducted to evaluate the <term sem="Other" id="T11" lex="cytokine_modulating_activity"><term sem="Protein_family_or_group" id="T12" lex="cytokine">cytokine</term> modulating activity</term> of <term sem="Organic_compound_other" id="T13" lex="tepoxalin">tepoxalin</term> and the role of <term sem="Element" id="T14" lex="iron">iron</term> in these effects.</sentence>
<event uncertainty="doubtful" id="E5">
<type class="Regulation" />
<theme idref="T12" />
<cause idref="T13" />
<clue>The current study was conducted to evaluate the cytokine <clueType>modulating activity</clueType> <linkCause>of</linkCause> tepoxalin and the role of iron in these effects.</clue>
</event>
<event uncertainty="doubtful" id="E6">
<type class="Regulation" />
<theme idref="E5" />
<cause idref="T14" />
<clue>The current study was conducted to evaluate the cytokine modulating activity of tepoxalin and the <clueType>role</clueType> <linkCause>of</linkCause> iron <linkTheme>in</linkTheme> <corefTheme>these effects</corefTheme>.</clue>
</event>
<sentence id="S5">In <term sem="Cell_natural" id="T15" lex="human_peripheral_blood_mononuclear_cell">human peripheral blood mononuclear cells</term> (<term sem="Cell_natural" id="T16" lex="PBMC">PBMC</term>) stimulated with <term sem="Organic_compound_other" id="T17" lex="OKT3/PMA"><term sem="Protein_family_or_group" id="A3">OKT3</term>/<term sem="Organic_compound_other" id="A4">PMA</term></term>, <term sem="Organic_compound_other" id="T18" lex="tepoxalin">tepoxalin</term> inhibited <term sem="Cell_natural" id="T19" lex="lymphocyte">lymphocyte</term> proliferation with an <term sem="Other" id="T20" lex="IC50">IC50</term> of 6 microM.</sentence>
<event id="E7">
<type class="Cellular_physiological_process" />
<theme idref="T19" />
<clue>In human peripheral blood mononuclear cells (PBMC) stimulated with OKT3/PMA, tepoxalin inhibited lymphocyte <clueType>proliferation</clueType> with an IC50 of 6 microM.</clue>
</event>
<event id="E8">
<type class="Negative_regulation" />
<theme idref="E7" />
<cause idref="T18" />
<clue><clueLoc>In human peripheral blood mononuclear cells (PBMC) stimulated with OKT3/PMA</clueLoc>, tepoxalin <clueType>inhibited</clueType> lymphocyte proliferation with an IC50 of 6 microM.</clue>
</event>
<event id="E9">
<type class="Physiological_process" />
<theme idref="T16" />
<cause idref="A3" />
<clue>In human peripheral blood mononuclear cells (PBMC) <clueType>stimulated</clueType> <linkCause>with</linkCause> OKT3/PMA, tepoxalin inhibited lymphocyte proliferation with an IC50 of 6 microM.</clue>
</event>
<event id="E10">
<type class="Physiological_process" />
<theme idref="T16" />
<cause idref="A4" />
<clue>In human peripheral blood mononuclear cells (PBMC) <clueType>stimulated</clueType> <linkCause>with</linkCause> OKT3/PMA, tepoxalin inhibited lymphocyte proliferation with an IC50 of 6 microM.</clue>
</event>
<sentence id="S6">Additionally, it inhibited the production of <term sem="Protein_molecule" id="T21" lex="LTB4">LTB4</term> (IC50 = 0.5 microM) and the <term sem="Protein_family_or_group" id="T22" lex="cytokine">cytokines</term> <term sem="Protein_molecule" id="T23" lex="IL-2">IL-2</term>, <term sem="Protein_molecule" id="T24" lex="IL-6">IL-6</term> and <term sem="Protein_molecule" id="T25" lex="TNF_alpha">TNF alpha</term> (IC50 = 10-12 microM).</sentence>
<event id="E11">
<type class="Gene_expression" />
<theme idref="T21" />
<clue>Additionally, it inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E12">
<type class="Gene_expression" />
<theme idref="T23" />
<clue>Additionally, it inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E13">
<type class="Gene_expression" />
<theme idref="T24" />
<clue>Additionally, it inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E14">
<type class="Gene_expression" />
<theme idref="T25" />
<clue>Additionally, it inhibited the <clueType>production</clueType> <linkTheme>of</linkTheme> LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E15">
<type class="Negative_regulation" />
<theme idref="E11" />
<cause idref="T18" />
<clue>Additionally, <corefCause>it</corefCause> <clueType>inhibited</clueType> the production of LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E16">
<type class="Negative_regulation" />
<theme idref="E12" />
<cause idref="T18" />
<clue>Additionally, <corefCause>it</corefCause> <clueType>inhibited</clueType> the production of LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E17">
<type class="Negative_regulation" />
<theme idref="E13" />
<cause idref="T18" />
<clue>Additionally, <corefCause>it</corefCause> <clueType>inhibited</clueType> the production of LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<event id="E18">
<type class="Negative_regulation" />
<theme idref="E14" />
<cause idref="T18" />
<clue>Additionally, <corefCause>it</corefCause> <clueType>inhibited</clueType> the production of LTB4 (IC50 = 0.5 microM) and the cytokines IL-2, IL-6 and TNF alpha (IC50 = 10-12 microM).</clue>
</event>
<sentence id="S7"><term sem="Other" id="T26" lex="cytotoxicity">Cytotoxicity</term> was not demonstrated at these concentrations.</sentence>
<sentence id="S8">Add-back experiments with either <term sem="Protein_family_or_group" id="T27" lex="cytokine">cytokines</term> (<term sem="Protein_molecule" id="T28" lex="IL-2">IL-2</term> or <term sem="Protein_molecule" id="T29" lex="IL-6">IL-6</term>), <term sem="Protein_molecule" id="T30" lex="LTB4">LTB4</term> or <term sem="Organic_compound_other" id="A6">conditioned media</term> failed to restore the proliferative response in the presence of <term sem="Organic_compound_other" id="T31" lex="tepoxalin">tepoxalin</term>.</sentence>
<event assertion="non-exist" id="E19">
<type class="Negative_regulation" />
<theme idref="E8" />
<cause idref="T28" />
<clue>Add-back experiments with either cytokines (IL-2 or IL-6), LTB4 or conditioned media <clueType>failed to restore</clueType> <linkTheme>the proliferative response in the presence of tepoxalin</linkTheme>.</clue>
<comment>CAUTION: restore</comment>
</event>
<event assertion="non-exist" id="E20">
<type class="Negative_regulation" />
<theme idref="E8" />
<cause idref="T29" />
<clue>Add-back experiments with either cytokines (IL-2 or IL-6), LTB4 or conditioned media <clueType>failed to restore</clueType> <linkTheme>the proliferative response in the presence of tepoxalin</linkTheme>.</clue>
<comment>CAUTION: restore</comment>
</event>
<event assertion="non-exist" id="E21">
<type class="Negative_regulation" />
<theme idref="E8" />
<cause idref="T30" />
<clue>Add-back experiments with either cytokines (IL-2 or IL-6), LTB4 or conditioned media <clueType>failed to restore</clueType> <linkTheme>the proliferative response in the presence of tepoxalin</linkTheme>.</clue>
<comment>CAUTION: restore</comment>
</event>
<event assertion="non-exist" id="E22">
<type class="Negative_regulation" />
<theme idref="E8" />
<cause idref="A6" />
<clue>Add-back experiments with either cytokines (IL-2 or IL-6), LTB4 or conditioned media <clueType>failed to restore</clueType> <linkTheme>the proliferative response in the presence of tepoxalin</linkTheme>.</clue>
<comment>CAUTION: restore</comment>
</event>
<sentence id="S9">However, the concurrent addition of <term sem="Element" id="T32" lex="iron">iron</term> (in the form of <cons sem="(OR Inorganic_compound Inorganic_compound)" id="T33" lex="(OR ferrous_chloride ferric_chloride)"><frag id="F1">ferrous</frag> or <frag id="F2">ferric</frag> <frag id="F3">chloride</frag></cons> and other <term sem="Inorganic_compound" id="T34" lex="iron_salt"><term sem="Element" id="T35" lex="iron">iron</term> salts</term>) reversed the inhibition of <term sem="Other" id="A7">proliferation</term> caused by <term sem="Organic_compound_other" id="T36" lex="tepoxalin">tepoxalin</term>.</sentence>
<event id="E23">
<type class="Negative_regulation" />
<theme idref="A7" />
<cause idref="T36" />
<clue>However, the concurrent addition of iron (in the form of ferrous or ferric chloride and other iron salts) reversed the <clueType>inhibition</clueType> <linkTheme>of</linkTheme> proliferation caused <linkCause>by</linkCause> tepoxalin.</clue>
</event>
<event id="E24">
<type class="Negative_regulation" />
<theme idref="E23" />
<cause idref="T32" />
<clue>However, the concurrent addition of iron (in the form of ferrous or ferric chloride and other iron salts) <clueType>reversed</clueType> the inhibition of proliferation caused by tepoxalin.</clue>
</event>
<sentence id="S10"><term sem="Organic_compound_other" id="T37" lex="tepoxalin">Tepoxalin</term> also inhibits the activation of <term sem="Protein_molecule" id="T38" lex="NF_kappa_B">NF kappa B</term>, a <term sem="Protein_family_or_group" id="T39" lex="transcription_factor">transcription factor</term> which acts on several <term sem="DNA_family_or_group" id="T40" lex="cytokine_gene">cytokine genes</term>.</sentence>
<event id="E25">
<type class="Positive_regulation" />
<theme idref="T38" />
<clue>Tepoxalin also inhibits the <clueType>activation</clueType> <linkTheme>of</linkTheme> NF kappa B, a transcription factor which acts on several cytokine genes.</clue>
</event>
<event id="E26">
<type class="Negative_regulation" />
<theme idref="E25" />
<cause idref="T37" />
<clue>Tepoxalin also <clueType>inhibits</clueType> the activation of NF kappa B, a transcription factor which acts on several cytokine genes.</clue>
</event>
<event id="E27">
<type class="Regulation" />
<theme idref="T40" />
<cause idref="T38" />
<clue>Tepoxalin also inhibits the activation of NF kappa B, a transcription factor which <clueType>acts</clueType> <linkTheme>on</linkTheme> several cytokine genes.</clue>
</event>
<sentence id="S11"><term sem="Organic_compound_other" id="T41" lex="tepoxalin">Tepoxalin</term>&apos;s effect on <term sem="Protein_molecule" id="T42" lex="NF_kappa_B">NF kappa B</term> is also reversed by the addition of <term sem="Inorganic_compound" id="T43" lex="iron_salt"><term sem="Element" id="T44" lex="iron">iron</term> salts</term>.</sentence>
<event id="E28">
<type class="Regulation" />
<theme idref="T42" />
<cause idref="T41" />
<clue>Tepoxalin&apos;s <clueType>effect</clueType> <linkTheme>on</linkTheme> NF kappa B is also reversed by the addition of iron salts.</clue>
</event>
<event id="E29">
<type class="Negative_regulation" />
<theme idref="E28" />
<cause idref="T43" />
<clue>Tepoxalin&apos;s effect on NF kappa B is also <clueType>reversed</clueType> <linkCause>by</linkCause> the addition of iron salts.</clue>
</event>
<sentence id="S12">These data suggest that the action of <term sem="Organic_compound_other" id="T45" lex="tepoxalin">tepoxalin</term> to inhibit <term sem="Other" id="T46" lex="proliferation">proliferation</term> in <term sem="Cell_natural" id="T47" lex="PBMC">PBMC</term> may be at least in part due to its ability to reduce the amount of available <term sem="Element" id="T48" lex="iron">iron</term> resulting in decreased activation of <term sem="Protein_molecule" id="T49" lex="NF_kappa_B">NF kappa B</term> and subsequent <term sem="Other" id="T50" lex="inhibition">inhibition</term> of <term sem="Other" id="T51" lex="cytokine_production"><term sem="Protein_family_or_group" id="T52" lex="cytokine">cytokine</term> production</term>.</sentence>
<event id="E61">
<type class="Cellular_physiological_process" />
<theme idref="T47" />
<clue>These data suggest that the action of tepoxalin to inhibit <clueType>proliferation</clueType> <linkTheme>in</linkTheme> PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event id="E30">
<type class="Negative_regulation" />
<theme idref="E61" />
<cause idref="T45" />
<clue>These data suggest that the action of tepoxalin to <clueType>inhibit</clueType> proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event id="E31">
<type class="Negative_regulation" />
<theme idref="T48" />
<cause idref="T45" />
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to <clueType>reduce</clueType> the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event id="E33">
<type class="Positive_regulation" />
<theme idref="T49" />
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased <clueType>activation</clueType> <linkTheme>of</linkTheme> NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event uncertainty="probable" id="E34">
<type class="Negative_regulation" />
<theme idref="E33" />
<cause idref="E31" />
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in <clueType>decreased</clueType> activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
<event id="E35">
<type class="Gene_expression" />
<theme idref="T52" />
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine <clueType>production</clueType>.</clue>
</event>
<event uncertainty="probable" id="E36">
<type class="Negative_regulation" />
<theme idref="E35" />
<cause idref="E34" />
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part due to its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent <clueType>inhibition</clueType> <linkTheme>of</linkTheme> cytokine production.</clue>
</event>
<event uncertainty="probable" id="E62">
<type class="Positive_regulation" />
<theme idref="E30" />
<cause idref="E36" />
<clue>These data suggest that the action of tepoxalin to inhibit proliferation in PBMC may be at least in part <clueType>due</clueType> <linkTheme>to</linkTheme> its ability to reduce the amount of available iron resulting in decreased activation of NF kappa B and subsequent inhibition of cytokine production.</clue>
</event>
</AbstractText>
</Abstract>
</Article>
</MedlineCitation>
</PubmedArticle>
</PubmedArticleSet>
</Annotation>
